07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

University of Oxford, Rogne Bioscience deal

The university’s Isis Innovation Ltd. tech transfer arm granted Rogne an exclusive, worldwide license to anti-inflammatory peptides. The deal includes C15 , a peptide derived from chemerin that inhibits production of the proinflammatory cytokines IL-12...
07:00 , Oct 21, 2010 |  BC Innovations  |  Cover Story

BET-ting on bromodomains

Although histone deacetylases are well-trodden, validated targets, 1 the therapeutic potential of inhibiting other aspects of the histone acetylation machinery has remained an open question. Now, a team led by the Dana-Farber Cancer Institute and...
07:00 , Oct 7, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Epithelial cancer Bromodomain containing 4 (BRD4); NUT midline carcinoma1 (NUTM1; NUT; C15 or f55) An in vitro and mouse study...
07:00 , Jun 25, 2009 |  BC Innovations  |  Cover Story

Low-Rhes approach to Huntington's

A central mystery of Huntington's disease has been why the mutant form of the huntingtin protein responsible for the condition is found throughout the body but only causes pathology in the brain's corpus striatum. Researchers...
08:00 , Dec 16, 1996 |  BC Week In Review  |  Clinical News

MDX-22-treated bone marrow data

Results from 138 patients in an ongoing Phase II trial show that 36 percent of patients who received MDX-22-treated marrow while in a second or third remission have achieved two years of disease-free survival. The...